JP2016503059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503059A5 JP2016503059A5 JP2015549613A JP2015549613A JP2016503059A5 JP 2016503059 A5 JP2016503059 A5 JP 2016503059A5 JP 2015549613 A JP2015549613 A JP 2015549613A JP 2015549613 A JP2015549613 A JP 2015549613A JP 2016503059 A5 JP2016503059 A5 JP 2016503059A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- light chain
- amino acid
- acid sequence
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 230000004988 N-glycosylation Effects 0.000 claims description 16
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000031886 HIV Infections Diseases 0.000 claims description 4
- 208000037357 HIV infectious disease Diseases 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 150000001720 carbohydrates Chemical group 0.000 claims description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 241000283080 Proboscidea <mammal> Species 0.000 claims 2
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 230000000644 propagated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261738777P | 2012-12-18 | 2012-12-18 | |
| US61/738,777 | 2012-12-18 | ||
| US201361864942P | 2013-08-12 | 2013-08-12 | |
| US61/864,942 | 2013-08-12 | ||
| PCT/US2013/076051 WO2014100139A1 (en) | 2012-12-18 | 2013-12-18 | Glycan-modified anti-cd4 antibodies for hiv prevention and therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503059A JP2016503059A (ja) | 2016-02-01 |
| JP2016503059A5 true JP2016503059A5 (enExample) | 2016-03-10 |
| JP6408487B2 JP6408487B2 (ja) | 2018-10-24 |
Family
ID=50979141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549613A Active JP6408487B2 (ja) | 2012-12-18 | 2013-12-18 | Ｈｉｖの防止および療法のためのグリカン修飾された抗ｃｄ４抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9790276B2 (enExample) |
| EP (1) | EP2934589B1 (enExample) |
| JP (1) | JP6408487B2 (enExample) |
| CN (1) | CN105228650B (enExample) |
| ES (1) | ES2862950T3 (enExample) |
| TW (1) | TWI630215B (enExample) |
| WO (1) | WO2014100139A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9587022B2 (en) | 2012-12-18 | 2017-03-07 | The Rockefeller University | Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| AU2014360760B2 (en) | 2013-12-02 | 2019-12-12 | The Trustees Of Columbia University In The City Of New York | Improved HIV-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture |
| EP3261651B1 (en) * | 2015-02-27 | 2022-05-04 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| JP6936221B2 (ja) * | 2015-11-02 | 2021-09-15 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用 |
| US11472889B2 (en) | 2017-10-14 | 2022-10-18 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| CN114269778B (zh) * | 2019-08-19 | 2024-10-01 | 洛克菲勒大学 | 具改良药物动力学的经酸碱度依赖性抗原结合活性工程化的抗人类免疫缺乏病毒抗体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| AU662891B2 (en) | 1990-11-27 | 1995-09-21 | Biogen Idec Ma Inc. | Anti CD-4 antibodies blocking HIV-induced syncytia |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| ATE440959T1 (de) | 2000-06-28 | 2009-09-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
| EP1888637A2 (en) * | 2005-05-19 | 2008-02-20 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| CA2632828C (en) * | 2005-12-12 | 2012-07-10 | F. Hoffmann-La Roche Ag | Antibodies against amyloid beta with glycosylation in the variable region |
| WO2008134046A1 (en) | 2007-04-27 | 2008-11-06 | Genentech, Inc. | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
| US9156912B2 (en) * | 2008-12-12 | 2015-10-13 | The University Of Tokyo | Immunological reconstitution promoter or prophylactic agent for infections each of which maintains graft-versus-tumor effect |
| WO2011116387A1 (en) * | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
| CN103282385A (zh) * | 2010-11-12 | 2013-09-04 | 美国洛克菲勒大学 | 用于hiv治疗的融合蛋白 |
| US9587022B2 (en) | 2012-12-18 | 2017-03-07 | The Rockefeller University | Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity |
-
2013
- 2013-12-18 TW TW102147105A patent/TWI630215B/zh active
- 2013-12-18 CN CN201380073311.4A patent/CN105228650B/zh active Active
- 2013-12-18 WO PCT/US2013/076051 patent/WO2014100139A1/en not_active Ceased
- 2013-12-18 US US14/132,667 patent/US9790276B2/en active Active
- 2013-12-18 JP JP2015549613A patent/JP6408487B2/ja active Active
- 2013-12-18 EP EP13866337.2A patent/EP2934589B1/en active Active
- 2013-12-18 ES ES13866337T patent/ES2862950T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018064580A5 (enExample) | ||
| Vanderven et al. | The protective potential of Fc‐mediated antibody functions against influenza virus and other viral pathogens | |
| Nguyen et al. | Neutralization of pertussis toxin by a single antibody prevents clinical pertussis in neonatal baboons | |
| Jayasekera et al. | Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity | |
| JP2017531642A5 (enExample) | ||
| JP2010521147A5 (enExample) | ||
| Whaley et al. | Emerging antibody products and Nicotiana manufacturing | |
| HRP20241498T1 (hr) | Antitijela usmjerena protiv t-staničnog imunoglobulina i mucin proteina 3 (tim-3) | |
| JP2013531993A5 (enExample) | ||
| HRP20191334T1 (hr) | Anti-fcrn antitijela | |
| FI3083694T3 (fi) | Kaninisoituja hiiren anti-koira-pd-1 -vasta-aineita | |
| JP2014526898A5 (enExample) | ||
| JP2016065094A5 (enExample) | ||
| JP2012121878A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| HRP20240774T1 (hr) | Anti-il-33 antitijela i njihove upotrebe | |
| JP2011173914A5 (enExample) | ||
| EP4653051A3 (en) | Human antibodies to ebola virus glycoprotein | |
| JP2012254092A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| NZ612315A (en) | Compositions for immunising against staphylococcus aureus | |
| JP2016500673A5 (enExample) | ||
| JP2015522252A5 (enExample) | ||
| HRP20221260T1 (hr) | Humanizirana i kimerna monoklonska protutijela za cd47 | |
| JP2015525795A5 (enExample) |